Literature DB >> 16140397

Pneumococcal conjugate vaccination in children with recurrent acute otitis media: a therapeutic alternative?

Muriel J P van Kempen1, Judith S Vermeiren, Mario Vaneechoutte, Geert Claeys, Reinier H Veenhoven, Ger T Rijkers, Elisabeth A M Sanders, Ingeborg J Dhooge.   

Abstract

BACKGROUND: Based on two clinical trials in healthy infants the American Academy of Pediatrics (AAP) advices immunization with a 7-valent pneumococcal conjugate vaccine in children with recurrent acute otitis media (AOM).
OBJECTIVE: To study the efficacy of a 7-valent pneumococcal conjugate vaccine on acute otitis media recurrences, its immunogenicity and impact on nasopharyngeal Streptococcus pneumoniae carriage in children with a history of frequent acute otitis media.
METHODS: In this double-blind, randomized study, 74 Belgian children, aged 1-7 years, with at least 2 clinically diagnosed episodes of acute otitis media in the previous year were enrolled. Children were immunized with either a 7-valent pneumococcal conjugate vaccine followed by a 23-valent pneumococcal polysaccharide booster or a control hepatitis A vaccine. Total follow-up was 26 months.
RESULTS: Despite adequate serum IgG responses to all conjugate vaccine pneumococcal serotypes, no reduction of acute otitis media episodes was observed in the pneumococcal vaccine group as compared to the control group (rate ratio: 1.16; 95% CI: 0.69-1.96). Overall nasopharyngeal pneumococcal carriage remained stable. However, a transient shift from conjugate vaccine related S. pneumoniae serogroups to non-vaccine related serogroups was noted following conjugate vaccination.
CONCLUSION: Clinically no protective effect of pneumococcal conjugate vaccination on acute otitis media recurrences was found in children with a history of frequent AOM.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16140397     DOI: 10.1016/j.ijporl.2005.06.022

Source DB:  PubMed          Journal:  Int J Pediatr Otorhinolaryngol        ISSN: 0165-5876            Impact factor:   1.675


  8 in total

1.  In VitroStreptococcus pneumoniae Biofilm Formation and In Vivo Middle Ear Mucosal Biofilm in a Rat Model of Acute Otitis Induced by S. pneumoniae.

Authors:  Mukesh Kumar Yadav; Sung-Won Chae; Jae-Jun Song
Journal:  Clin Exp Otorhinolaryngol       Date:  2012-08-27       Impact factor: 3.372

2.  Otitis Media: A Review, with a Focus on Alternative Treatments.

Authors:  L M T Dicks; H Knoetze; C A van Reenen
Journal:  Probiotics Antimicrob Proteins       Date:  2009-03-04       Impact factor: 5.265

3.  Pneumococcal conjugate vaccines for preventing acute otitis media in children.

Authors:  Alexandre C Fortanier; Roderick P Venekamp; Chantal Wb Boonacker; Eelko Hak; Anne Gm Schilder; Elisabeth Am Sanders; Roger Amj Damoiseaux
Journal:  Cochrane Database Syst Rev       Date:  2019-05-28

4.  Pneumococcal conjugate vaccines for preventing acute otitis media in children.

Authors:  Joline Lh de Sévaux; Roderick P Venekamp; Vittoria Lutje; Eelko Hak; Anne Gm Schilder; Elisabeth Am Sanders; Roger Amj Damoiseaux
Journal:  Cochrane Database Syst Rev       Date:  2020-11-24

5.  Pneumococcal conjugate vaccines reduce myringotomy with tympanostomy tube insertion in young children in Japan.

Authors:  Yui Ogawa; Masaru Kunimoto; Sachio Takeno; Toru Sonoyama; Takashi Ishino; Takao Hamamoto; Tsutomu Ueda
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-12-11

Review 6.  Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective.

Authors:  Catherine Weil-Olivier; Mark van der Linden; Iris de Schutter; Ron Dagan; Lorenzo Mantovani
Journal:  BMC Infect Dis       Date:  2012-09-07       Impact factor: 3.090

Review 7.  What is new in otitis media?

Authors:  Lucien Corbeel
Journal:  Eur J Pediatr       Date:  2007-03-16       Impact factor: 3.183

8.  Otitis media: viruses, bacteria, biofilms and vaccines.

Authors:  Helen M Massa; Allan W Cripps; Deborah Lehmann
Journal:  Med J Aust       Date:  2009-11-02       Impact factor: 7.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.